WATERTOWN, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the following upcoming investor conferences:
  • Rodman & Renshaw 19 th Annual Global Investment Conference on Monday, September 11 th, 2017 at 12:30 p.m. Eastern Time at the Lotte New York Palace Hotel in New York City  
  • Cantor Fitzgerald Global Healthcare Conference on Monday, September 25 th at 1:50 p.m. Eastern Time at the InterContinental New York Barclay Hotel in New York City

Live audio webcasts of the presentations will be available on the company's website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.

Investor Contacts:Tetraphase PharmaceuticalsTeri Dahlman	617-600-7040	tdahlman@tphase.comArgot PartnersMaeve Conneighton206-899-4940maeve@argotpartners.comMedia Contact:Sam Brown Inc.Mike Beyer312-961-2502mikebeyer@sambrown.com

Primary Logo